{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T06:34:17Z","timestamp":1770446057573,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.vaccine.2016.12.014","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T02:05:20Z","timestamp":1482458720000},"page":"570-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The economic impact of prenatal varicella immunity among pregnant women in Alberta"],"prefix":"10.1016","volume":"35","author":[{"given":"Amrit","family":"Passi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina S.","family":"Plitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberley","family":"Simmonds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen L.","family":"Charlton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8659","key":"10.1016\/j.vaccine.2016.12.014_b0005","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0140-6736(89)90547-3","article-title":"Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus","volume":"2","author":"Miller","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2016.12.014_b0010","series-title":"Varicella-ZosterVirus Virology and Clinical Management","first-page":"317","article-title":"Varicella and herpes zoster in pregnancy and thenewborn","author":"Enders","year":"2000"},{"issue":"2","key":"10.1016\/j.vaccine.2016.12.014_b0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4236\/health.2010.22022","article-title":"Review of varicella-zoster virus infections in pregnant women and neonates","volume":"2","author":"Sauerbrei","year":"2010","journal-title":"Health"},{"key":"10.1016\/j.vaccine.2016.12.014_b0020","unstructured":"Branch DCAP [internet]. Alberta Prenatal Screening Program for Selected Communicable Diseases. Alberta Health and Wellness; 2006. Available from: <http:\/\/www.health.alberta.ca\/documents\/Prenatal-Screening-Program-July-2007.pdf>."},{"key":"10.1016\/j.vaccine.2016.12.014_b0025","unstructured":"National Advisory Committee on Immunization [internet]. Update on varicella. Can Commun Dis Rep. 2004; 30(ACS-1): 1\u201328. Available from: <http:\/\/www.phac-aspc.gc.ca\/publicat\/ccdr-rmtc\/04vol30\/acs-dcc-1\/index-eng.php>."},{"key":"10.1016\/j.vaccine.2016.12.014_b0030","unstructured":"National Advisory Committee on Immunization [internet]. Varicella Vaccination Two-Dose Recommendations. Can Commun Dis Rep. 2010; 36: ACS-8. Available from: <http:\/\/www.phac-aspc.gc.ca\/publicat\/ccdr-rmtc\/10vol36\/acs-8\/index-eng.php>."},{"key":"10.1016\/j.vaccine.2016.12.014_b0035","unstructured":"Siemens. Enzygnost\u00ae Anti-VZV\/IgG: package insert. Siemens Healthcare Diagnostics Products GmbH; 2008."},{"key":"10.1016\/j.vaccine.2016.12.014_b0040","unstructured":"Alberta Health [internet]. Notifiable diseases: age-sex specific incidence rate (common diseases). Interactive Health Data Application; 2016. Available from: <http:\/\/www.ahw.gov.ab.ca\/IHDA_Retrieval\/selectSubCategoryParameters.do>."},{"issue":"1","key":"10.1016\/j.vaccine.2016.12.014_b0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jviromet.2004.02.012","article-title":"Immunofluorescence test for sensitive detection of varicella-zoster virus-specific IgG: an alternative to fluorescent antibody to membrane antigen test","volume":"119","author":"Sauerbrei","year":"2004","journal-title":"J Virol Meth"},{"issue":"11","key":"10.1016\/j.vaccine.2016.12.014_b0050","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1128\/JCM.25.11.2059-2062.1987","article-title":"Comparison of five assays for antibody to varicella-zoster virus and the fluorescent-antibody-to-membrane-antigen test","volume":"25","author":"Larussa","year":"1987","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2016.12.014_b0055","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1086\/501900","article-title":"Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers","volume":"22","author":"Saiman","year":"2001","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"6","key":"10.1016\/j.vaccine.2016.12.014_b0060","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/infdis\/130.6.669","article-title":"Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence","volume":"130","author":"Williams","year":"1974","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.014_b0065","series-title":"Human herpesviruses: biology,therapy, and immunoprophylaxis.","article-title":"VSV: persistence in the population","author":"Seward","year":"2007"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2016.12.014_b0070","article-title":"Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure","volume":"178","author":"Mandal","year":"1998","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2016.12.014_b0075","doi-asserted-by":"crossref","first-page":"ofv006","DOI":"10.1093\/ofid\/ofv006","article-title":"Seroprevalence of measles, mumps, rubella and varicella antibodies in the United States population, 2009\u20132010","volume":"2","author":"Lebo","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2016.12.014_b0080","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.epidem.2014.12.005","article-title":"The social contact hypothesis under the assumption of endemic equilibrium: elucidating the transmission potential of VZV in Europe","volume":"11","author":"Santermans","year":"2015","journal-title":"Epidemics"},{"issue":"2","key":"10.1016\/j.vaccine.2016.12.014_b0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1620\/tjem.234.111","article-title":"Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital","volume":"234","author":"Kanamori","year":"2014","journal-title":"Tohoku J Exp Med"},{"issue":"11","key":"10.1016\/j.vaccine.2016.12.014_b0090","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1017\/S0950268816000595","volume":"144","author":"Maple","year":"2016","journal-title":"Epidemiol Infect"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1631221X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1631221X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T05:23:03Z","timestamp":1601270583000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1631221X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0264410X1631221X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.014","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The economic impact of prenatal varicella immunity among pregnant women in Alberta","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}